The company said full-year 2024 revenues were $63.6 billion, up 7% from a year earlier, and that excluding contributions from Paxlovid and Comirnaty, revenues grew 12% operationally.

1. 01

   The company said full-year 2024 revenues were $63.6 billion, up 7% from a year earlier, and that excluding contributions from Paxlovid and Comirnaty, revenues grew 12% operationally.

2. 02

   The company reported net income attributable to the company of $410 million for Q4 2024 (diluted EPS of $0.07) and adjusted diluted EPS of $0.63, compared with a net loss of $(3,369) million in the year-earlier period.

3. 03

   The company said the Q4 2024 Other (income)/deductions—net included a non-cash intangible asset impairment charge of $2.9 billion taken due to changes in development plans and updated long-range commercial outlook.

4. 04

   The company gave full-year 2025 guidance of revenues of $61.0 billion to $64.0 billion and adjusted diluted EPS of $2.80 to $3.00, and said its guidance assumes no share repurchases in 2025.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.